Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro

Detalles Bibliográficos
Autores principales: Yamada, Reiko, Steward, Kristopher, Ngarmchamnanrith, Gataree, Trinh, Ryan, Khare, Sanjay, Sachdev, Raj, Grewal, Iqbal, Morrison, Sherie, Timmerman, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991073/
http://dx.doi.org/10.1186/2051-1426-1-S1-P263
Descripción
Sumario:

Ejemplares similares